NASDAQ:CDXC
ChromaDex Corporation Stock News
$3.44
+0.0500 (+1.47%)
At Close: Apr 26, 2024
ChromaDex and Walmart Launch Tru Niagen® in 3,800 Walmart Stores Across the United States
06:33am, Monday, 07'th Jun 2021
LOS ANGELES--(BUSINESS WIRE)---- $CDXC #healthyaging--ChromaDex Corp. (NASDAQ:CDXC) announced today the launch of its flagship consumer product Tru Niagen® in Walmart, available in 3,800 stores acros
ChromaDex (CDXC) CEO Robert Fried on Q1 2021 Results - Earnings Call Transcript
11:25pm, Saturday, 08'th May 2021
ChromaDex (CDXC) CEO Robert Fried on Q1 2021 Results - Earnings Call Transcript
ChromaDex (CDXC) Reports Q1 Loss, Misses Revenue Estimates
07:32pm, Thursday, 06'th May 2021
ChromaDex (CDXC) delivered earnings and revenue surprises of -33.33% and -10.87%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
ChromaDex and Ro Partner for New Product Development
06:33am, Tuesday, 04'th May 2021
LOS ANGELES--(BUSINESS WIRE)---- $CDXC #collaboration--ChromaDex Corp. (NASDAQ:CDXC) announced today that it entered into a strategic supply agreement for Niagen® with Ro, a healthcare-technology com
ChromaDex to Report First Quarter 2021 Financial Results on Thursday, May 6, 2021
06:33am, Thursday, 29'th Apr 2021
LOS ANGELES--(BUSINESS WIRE)---- $CDXC #earnings--ChromaDex Corp. (NASDAQ:CDXC) announced that it will hold a conference call on Thurs., May 6, 2021 at 4:30 p.m. ET to discuss its financial results fo
ChromaDex and Health & Happiness (H&H) Group Announce Supply Agreement for Niagen®
06:33am, Wednesday, 28'th Apr 2021
LOS ANGELES--(BUSINESS WIRE)---- $CDXC #healthyaging--ChromaDex Corp. (NASDAQ:CDXC) announced today it entered into a strategic supply agreement with Health & Happiness (H&H) Group, a global leader in
ChromaDex Growth Story Just Getting Started: Interview With CEO Rob Fried
07:27pm, Wednesday, 21'st Apr 2021
Last week I was fortunate to meet Rob Fried, CEO of ChromaDex, in my podcast for a very interesting talk about his promising company. With its dietary supplement Tru Niagen, ChromaDex is at the forefr
ChromaDex: An Anti-Aging Company With Major New Deals
06:47am, Monday, 19'th Apr 2021
ChromaDex develops and sells an anti-aging drug called Tru Niagen.
ChromaDex Appoints Fadi Karam as Chief Marketing Officer
06:33am, Monday, 19'th Apr 2021
LOS ANGELES--(BUSINESS WIRE)---- $CDXC #management--ChromaDex Corp. (NASDAQ:CDXC) announced today that it has appointed Fadi Karam as Chief Marketing Officer. Karam has spent his career driving consum
ChromaDex and the Citrin Foundation Announce Global Research Collaboration Exploring Citrin Deficiency
06:33am, Wednesday, 31'st Mar 2021
LOS ANGELES--(BUSINESS WIRE)---- $CDXC #collaboration--ChromaDex Corp. (NASDAQ: CDXC) today announced a new research initiative with the Citrin Foundation of Singapore to study the effects of Niagen®
ChromaDex to Present at the Lytham Partners Spring 2021 Investor Conference
06:33am, Wednesday, 24'th Mar 2021
LOS ANGELES--(BUSINESS WIRE)---- $CDXC #healthyaging--ChromaDex Corp. (NASDAQ:CDXC) today announced that its Chief Executive Officer, Rob Fried, and Chief Financial Officer, Kevin Farr, will be presen
Is the Options Market Predicting a Spike in ChromaDex (CDXC) Stock?
09:50am, Monday, 22'nd Mar 2021
Investors need to pay close attention to ChromaDex (CDXC) stock based on the movements in the options market lately.
ChromaDex to Present at the Zooming with LD Virtual Investor Conference
06:33am, Thursday, 18'th Mar 2021
LOS ANGELES--(BUSINESS WIRE)---- $CDXC #healthyaging--ChromaDex Corp. (NASDAQ:CDXC) today announced that its Chief Executive Officer, Rob Fried, and Chief Financial Officer, Kevin Farr, will be presen
ChromaDex's (CDXC) CEO Rob Fried on Q4 2020 Results - Earnings Call Transcript
11:12pm, Wednesday, 10'th Mar 2021
ChromaDex's (CDXC) CEO Rob Fried on Q4 2020 Results - Earnings Call Transcript
ChromaDex (CDXC) Reports Q4 Loss, Tops Revenue Estimates
06:11pm, Wednesday, 10'th Mar 2021
ChromaDex (CDXC) delivered earnings and revenue surprises of 9.09% and 0.31%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
